Malaria JournalGeneticsPeer-reviewed journal article
Development of copy number assays for detection and surveillance of piperaquine resistance associated plasmepsin 2/3 copy number variation in Plasmodium falciparum
Christopher G. Jacob, Megan R. AnsbroiD, Roberto AmatoiD, Mihir Kekre, Ranitha Vongpromek, Mehul DhordaiD, Chanaki Amaratunga, Sokunthea Sreng, Seila Suon, Olivo MiottoiD, Rick M. Fairhurst, Thomas E. WellemsiD, Dominic P. KwiatkowskiiD
Abstract
Long regarded as an epicenter of drug-resistant malaria, Southeast Asia continues to provide new challenges to the control of Plasmodium falciparum malaria. Recently, resistance to the artemisinin combination therapy partner drug piperaquine has been observed in multiple locations across Southeast Asia. Genetic studies have identified a single nucleotide polymorphism as well as a copy number variation molecular marker that associate with clinical and in vitro resistance. The copy number polymorphism is a duplication of a region containing members of the plasmepsin multi-gene family of proteases. To accurately and quickly determine the presence of copy number variation in the plasmepsin 2/3 duplication in field isolates, we developed a quantitative PCR assay using TaqMan probes. We validated copy number estimates using a separate SYBR green-based quantitative PCR assay as well as a novel breakpoint assay to detect the hybrid gene product. Field samples from 2012 - 2015 across 3 sites in Cambodia were tested using DNA extracted from dried blood spots and whole blood to monitor the extent of plasmepsin 2/3 gene duplications, as well as pfmdr1. We found high concordance across all methods of copy number detection. For samples derived from dried blood spots we found a greater than 80% success rate in each assay, with more recent samples performing better. We found evidence of extensive plasmepsin 2/3 copy number amplifications in Pursat (94%, 2015) and Preah Vihear (87%, 2014), and lower levels in Ratanakiri (16%, 2014) in eastern Cambodia. We also see evidence of a shift from two copies of plasmepsin 2/3 in Pursat 2013 to three copies in 2014-15 (25% to 64%). Pfmdr1 duplications are absent from all samples in 2014 from Preah Vihear and Ratanakiri and 2015 from Pursat. This study shows increasing levels of plasmepsin 2/3 gene amplifications across Cambodia from 2012 - 2015 and a complete reversion of pfmdr1 mutant parasites in all study locations. The multiplex TaqMan assay is a robust tool for monitoring both plasmepsin and pfmdr1 copy number variations in field isolates, and the SYBR-green and breakpoint assays are useful for monitoring plasmepsin 2/3 duplications.
- Citations
- 38
- FWCI
- 4.12
- Field percentile
- top 5%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- High proportion of multiple copies of Plasmodium falciparum Plasmepsin-2 gene in African isolates: Is piperaquine resistance emerging in Africa?
D. Leroy, F. Macintyre, … D. Ménard·bioRxiv·Jul 3, 2018
- The Plasmepsin-Piperaquine Paradox Persists
Breanna Walsh, Robert L. Summers, … Selina E. R. Bopp·PLoS PathogensPeer-reviewed·Jul 28, 2025
- Pfcrt copy number amplification detected in a Plasmodium falciparum outbreak
Anjana Rai, Chiyun Lee, … Sarah Auburn·bioRxiv·Jun 19, 2026
- Emergence of Artemisinin-based Combination Therapy Resistance Markers in Plasmodium falciparum from the Brazilian Tri-Border Region of the Guiana Shield
Yanka Evellyn Alves Rodrigues Salazar, Antonio M. Rezende, … Taís Nóbrega de Sousa·Antimicrobial Agents and ChemotherapyPeer-reviewed·Mar 12, 2026
- Xeno-monitoring of molecular drivers of artemisinin and partner drug resistance in P. falciparum populations in malaria vectors across Cameroon
Francis Nongley Nkemngo, Leon M. J. Mugenzi, … Charles Sinclair Wondji·GenePeer-reviewed·Feb 17, 2022
- Origins of the current outbreak of multidrug resistant malaria in Southeast Asia: a retrospective genetic study
R. Amato, R. D. Pearson, … D. P. Kwiatkowski·bioRxiv·Oct 24, 2017